You are currently using an unsupported browser which could affect the appearance and functionality of this website. Please consider upgrading to the latest version or using alternatives such as Mozilla Firefox, Google Chrome or Microsoft Edge.

The Management of Women with Red Cell Antibodies during Pregnancy (Green-top Guideline No. 65)

Summary: This guideline provides guidance on the management of pregnant women with red cell antibodies predating the pregnancy or those developing antibodies during pregnancy. The guideline also includes the management of fetal anaemia caused by red cell antibodies, as well as the early management of the neonate at risk of anaemia and/or hyperbilirubinaemia. It does not address the management of the pregnant woman with anti-platelet antibodies or other autoimmune or alloimmune antibodies.

COVID disclaimer: This guideline was developed as part of the regular programme of Green-top Guidelines, as outlined in our document Developing a Green-top Guideline: Guidance for developers (PDF), and prior to the emergence of COVID-19.

Version history: This is the first edition of this guideline.

Developer declaration of interests: Available on request.

This page was last reviewed 28 May 2014.